Physician profile
David Rankine
NPI 1851349989
$166,611.84
in general payments reported to CMS, 2019-2025
22 companies · $5,578 in 2025
The $5,578 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,783 · 2020: $6,408 · 2021: $28K · 2022: $43K · 2023: $30K · 2024: $45K · 2025: $5,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Travel and Lodging: $2,688 · Consulting Fee: $2,400 · Food and Beverage: $1,548 · Education: $97.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,439.00 |
| Travel and Lodging | $2,687.97 |
| Consulting Fee | $2,400.00 |
| Food and Beverage | $1,547.64 |
| Education | $97.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $98,050.12 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $43,030.12 | 2021-2025 | |
| Ucb, INC. | $21,101.03 | 2019-2025 | Nayzilam, Briviact |
| Allergan, INC. | $3,342.63 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $213.67 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $195.41 | 2019 | |
| Argenx US, INC. | $122.78 | 2024 | Vyvgart |
| Neuronetics, INC. | $118.30 | 2019 | |
| Resmed Corp | $97.75 | 2025 | |
| Acadia Pharmaceuticals INC | $41.68 | 2019 | |
| Lundbeck LLC | $39.89 | 2020-2024 | Vyepti |
| Jazz Pharmaceuticals INC. | $35.92 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.41 | 2022 | |
| Ge Healthcare | $34.58 | 2019 | |
| Genzyme Corporation | $27.36 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $23.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.61 | 2019 | |
| Eisai INC. | $17.38 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.14 | 2019 | |
| Pfizer INC. | $16.33 | 2023 | |
| Acorda Therapeutics, INC | $15.17 | 2019 | |
| Amgen INC. | $14.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rankine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.